Intersect ENT (XENT) PT Raised to $40 at Leerink Partners Citing Early SINUVA Approval
Tweet Send to a Friend
Leerink Partners raised its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
